Therapeutic role of imatinib mesylate in chronic myeloid leukemia.
DOI:
https://doi.org/10.29309/TPMJ/2025.32.10.9812Keywords:
Chronic Myeloid Leukemia, HPLC, ImatinibAbstract
Objective: To evaluate the impact of demographic (age, gender) and genetic (rs683369) factors on the therapeutic response to Imatinib Mesylate. Study Design: Prospective, Non-interventional Observational Study. Setting: Islamic International Medical College and Holy Family Hospital, with Genetic Testing at KRL Hospital, Islamabad. Period: January 2019 to December 2022. Methods: Included 106 CML patients aged 18–75 years, receiving 400 mg/day of Imatinib Mesylate. Response was assessed after three months based on hematological markers and Philadelphia chromosome presence. rs683369 genotyping was performed using PCR-RFLP, and plasma Imatinib levels were measured after one month. Statistical analysis included chi-square tests and binary logistic regression using SPSS. Period: January 2019 to December 2022. Results: Gender was significantly associated with treatment response, with females showing a higher response rate (p < 0.001). Older patients (≥51 years) exhibited higher plasma drug levels. The CC genotype of rs683369 was significantly associated with a favorable response compared to CG and GG genotypes (p = 0.04). Conclusion: Age, gender, and rs683369 genotype significantly influence Imatinib response in Pakistani CML patients. These findings support the application of pharmacogenetics in developing personalized treatment strategies.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 The Professional Medical Journal

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.